Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENZC has so much going on that it is hard to grasp. They have in their arsenal the future of medical care in the way of therapeutic platforms first for HIV and Coronavirus and then for 14 more viruses.
The future of health
How innovation will blur traditional health care boundaries
The life sciences and health care industry is on the brink of large-scale disruption. In a future of health that’s defined by radically interoperable data, open yet secure platforms, and consumer-driven care, what role will you play?
In our vision of the future of health, we view radically interoperable data, artificial intelligence (AI), and open, secure platforms as central to the promise of more consumer-focused, prevention-oriented care. AI will enable major scientific breakthroughs, accelerating the creation of new therapies and vaccines to fight diseases. AI-enabled digital therapeutics and personalized recommendations will empower consumers to prevent health issues from developing. AI-generated insights will influence diagnosis and treatment choices, leading to safer and more effective treatments. Additionally, intelligent manufacturing and supply chain solutions will ensure the right treatments and interventions are delivered at the exact moment needed by the patient. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-health.html?id=us:2ps:3gl:fohc4:awa:lshc:121420:ad3:kwd-472491030708:the%20%2Bfuture%20of%20%2Bmedicine&gclid=CjwKCAiAsaOBBhA4EiwAo0_AnCsF0fPTERNdE4xTI2mbc961uiNTuuR1QoDHglNSC8VOJwNsgqwMIBoC5SoQAvD_BwE
Monoclonal Antibody Techniques
Monoclonal antibodies (mAbs) are monovalent antibodies which bind to the same epitope and are produced from a single B-lymphocyte clone. Monoclonal antibodies are important tools used in biomedical research, in diagnosis of diseases, and in treatment of such diseases as infections and cancer.
What is the value of monoclonal antibody technology?
Monoclonal antibody technology allows us to produce identical antibody molecules in large scale or industrial yields. It should be noted that the emergence of monoclonal antibody technology makes it possible for a variety of applicationsof monoclonal antibodies.
Single B cell antibody technologies
This approach to produce monoclonal antibodies from single human B cells is based on the analysis of the immunoglobulin gene repertoire and reactivity at the single-cell level by the application of reverse transcription-polymerase chain reaction (RT-PCR) and expression vector cloning.
By recognition of selected cell surface markers, individual mouse or human B cells are isolated (e.g., by fluorescence-activated cell sorting), and genes coding for VL and VH fragments are separately amplified by RT-PCR and combined by PCR. For the final production of human mAbs in vitro, H and L chain gene transcripts from each cell are amplified by RT-PCR before cloning and expression in a mammalian system. This method has the virtue of being able to produce many specific human mAbs in a short period. View more about "Single B cell antibody technologies".
https://www.sinobiological.com/resource/antibody-technical/monoclonal-antibody-technology
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. [color=green][/color]From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".[/color]
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. https://marketwirenews.com/news-releases/enzolytics-inc-engages-bts-research-to-conduct-toxic-6758170663840334.html
The toxicity test is a non-issue as we already know the expected results from the 2020 Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Also I don’t expect a press release on the website because once it is up and running there is no reason to tell us as we will already know.
https://twitter.com/SportsCardsTVMe/status/1361002549608931328
https://twitter.com/drgauravchandra/status/1361006189249757187?s=19
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.
Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.
Quote:
CEO Charles Cotropia stated, "The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU."
Quote:
CSO Harry Zhabilov stated, "With the Bulgarian Drug Administration joining the European Medicine Agency and being recognized under the Mutual Recognition Agreement with the FDA, once we have successfully finished the permitting process the Company will be able to pursue FDA approval for ITV-1. We are currently investigating the required steps but feel confident that this is a viable option for the ITV-1 patented therapy."
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
ENZC have accomplished many milestones to get their products to the marketplace. We come a long way in a short period of time however much more work is necessary and unforeseen circumstances to overcome such as the situation in Bulgaria. Getting our first product to the marketplace is a priority as it is needed and will be done as soon as possible. Whether that is weeks or months away is not only up to the company but also any requirements set forth by regulatory agencies as we have seen with the toxicity test. ENZC is fortunate to be at the The Texas A&M Institute for Preclinical Studies (TIPS)
Quote:
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry and engineering. This direct association with the College of Veterinary Medicine and Biomedical Sciences gives researchers the ability to pursue knowledge in a top research university, where cutting-edge technology and scientists at the head of their field can be accessed.
ENZC priority for obvious reasons is the monoclonal antibodies for HIV and CoronaVirus.
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
They are already working on 14 more prevalent viruses that they will eventually produce monoclonal antibodies to combat them.
The work ENZC is accomplishing is neither easy or quick however with the previous research and trials that have already taken place along with the laboratory at TIPS will certainly help in the process. There may be long stretches without press releases as the company works through the necessary processes to get their products to the marketplace. Patience is key and as long as Charles and team members take care of business everything else will fall into place as we have seen thus far.
Charles will release news when he has something to share.
Always have and Always will!
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
https://backend.otcmarkets.com/otcapi/company/financial-report/265788/content
Patent US-7479538
Enzolytics has a License Agreement for US Patent 7479538. The claim is Irreversibly-inactivated Pepsinogen Fragments for Modulating Immune Function.
https://enzolytics.com/patent
DA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
Our agency has had experience with evolving infectious diseases. Influenza vaccines and diagnostics are often modified each year to address the predicted predominant strains circulating globally. The agency has created and used regulatory processes that facilitate these updates. We will utilize our experience with influenza to help inform a path forward if SARS-CoV-2 variants emerge against which currently authorized vaccines are not sufficiently effective. Similarly, the FDA also has vast experience with HIV developing resistance to antiviral drugs and will follow regulatory pathways to quickly enable new antiviral drug development for resistant virus.
We have already been communicating with individual medical product sponsors to provide information as they evaluate the impact of COVID-19 variants on their products. And as part of our commitment to a public and transparent process, the FDA is developing guidances for diagnostic, therapeutic and vaccine developers to help guide ongoing medical product development.
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
For authorized vaccines, our teams are currently deliberating and discussing the types of data needed to support changes in the composition of the vaccine, either through altering the existing vaccine or through the addition of new vaccine component(s), including how sponsors could demonstrate immune response to new variants through streamlined clinical programs that still gather the crucial data the FDA needs to demonstrate effectiveness, but can be executed quickly to gather this data. To be clear, while we continue to develop an understanding of and address any impact of variants on FDA-regulated products, at this time, available information suggests that the authorized vaccines remain effective in protecting the American public against currently circulating strains of COVID-19.
The stock price will move according to the the results of the company. Besides the company unlimited potential, the minor results (getting current, new patent, hired PCAOB auditor, toxicity study etc..) management and board of directors has put ENZC on a trajectory of preeminence.
Will ENZC fill the shoes of such an important distinction?
Time will tell.
The company is just in the development stage with some powerful tools in their closet. The have some processes that the MUST go through to get to the final goals of getting products to the marketplace.
ENZC is very fortunate to be at Texas A&M Institute for Preclinical Studies(TIPS)
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry, and engineering.
ENZC have shared their plans, goals mission and commitments as well as updates along the way. What they have shared thus far is just a sliver of what is coming down the road.
We are not even 6 months into this journey and the attention the company is getting is unprecedented. They posses some unique technology that may be the answer to help shutting Covid-19 down or at least keeping it in check.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
The toxicity test is a non-issue as we already know the expected results from the 2020 Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Our treatment is a fraction of the cost for current treatment. We will be able to offer a less expensive product that more people will be able to afford and International aid agencies will purchase it to provide to third world countries.
Why is ENZC different from other antibodies?
CEOCFO: From your recent press release, you have a proprietary methodology for producing fully human OGG1 monoclonal antibodies. How is your approach different?
There are an infinite number of distinct anti-HIV and anti-CoronaVirus monoclonal antibodies that can exist – some disease neutralizing, some perhaps of no benefit and some perhaps disease enhancing. Thus, specific antibodies that neutralize are necessary to provide an effective therapy. Enzolytics’ method of producing effective monoclonal antibodies focuses on identifying immutable binding sites on the virus and then creating monoclonal antibodies that bind to such sites and neutralize the virus. In this way, the virus cannot mutate around the therapy. For example, the antibodies administered to President Trump to treat him for the CoronaVirus, may target a site on the virus that will mutate. Thus, the same antibodies may not be effective for you or me later if the CoronaVirus has mutated, changed structure, at this binding site. Our anti-HIV monoclonal antibody binds to a site on the HIV virus that is conserved in 98% of the more than 6000 strains of the HIV-1 viruses now known, sequenced and archived in the Los Alamos National Laboratory HIV Database. The same will have to be achieved for successful anti-CoronaVirus monoclonal antibodies.
CEOCFO: From your recent press release, you have a proprietary methodology for producing fully human OGG1 monoclonal antibodies. How is your approach different?
In contrast, our method starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the target virus. The primary distinction of our process for creating fully human monoclonals is the starting point – namely from human “immune-B cells” obtained from humans who have survived successfully from a "natural" infection. From these human “immune-B cells”, we then produce antibodies that target conserved immutable sites (neutralizable epitopes) on the virus’ surface envelope proteins – which will thereby avoid “virus escape”, which has been frequently demonstrated to occur as a consequence of mutations in the HIV virus surface structure.
Additionally, our antibodies retain the original natural antibody affinity and specificity, and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, in what is called the camelid structure form, and, in the recombinant form will have greater accessibility to the virus binding sites not accessible with a whole antibody. We believe that our method is one that produces an antibody which will be more effective with less risk of adverse reaction.
Source: https://www.ceocfointerviews.com/enzolytics20.html
Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?
CEOCFO: What are you looking at regarding COVID?
Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.
For example, we all now know that President Trump received a combination of two Regeneron antibodies. Eli Lilly has also produced an anti-CoronaVirus antibody. However, what we do not know is whether those antibodies will be successful as the virus mutates. As I mentioned, there are now known 16,000 different variants to the CoronaVirus and immutable sites must be the targeted in order to be effective in the long run.
Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. The process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.
Very very HUGE OTC LESSON HERE:
Multiple Millionaires have been made and more WILL BE MADE as ENZC's stock price APPRECIATES!!!
Why?
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
SPRING is in the Air
BOOM Time COMING
For people coming here ASKING for links to CLINICAL trials on ENZC product it is all a farce as information is widely available on the WORLD WIDE WEB!!!
ENZC has done clinical trials in the past and will be doing clinical trials in the near future in EUROPE.
COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen.
ENZC already passed Phase III trials. 80% kill rate of HIV:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158404062
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that is expected to be required under EMA standards. In addition, the Company is negotiating with an International known and respected European Contract Manufacturing organization ("CMO") to manufacture the required quantities of the ITV-1 Treatment to facilitate the clinical trials and permitting process under EMA guidelines.
Enzolytics, Inc. (ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind.
Where did ENZC come from:
PLANO, TX / ACCESSWIRE / September 16, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas.
About Enzolytics, Inc;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be use to produce therapeutics treatments for name infectious diseases including the Coronavirus.
What are they doing?
On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple anti-CoronaVirus monoclonal antibodies for use as a therapeutic against the SARS-CoV-2 virus.
On December 1, 2020, the combination agreement was completed, and the control block of shares of Enzolytics was transferred in accordance with the terms of the final document to Dr. Joseph Cotropia, Dr. Gaurav Chandra, and me, officially integrating the management teams and organizations into one single-purposed organization.
Enzolytics Inc. brings to the table ITV-1 and BioClonetics Immunotherapeutics, Inc. brings fully human monoclonal antibodies (mAbs).
The therapies of Enzolytics' two technologies, that produced by Enzolytics and that created by BioClonetics will be tested in combination and are expected to be synergistic.
Is it cost effective?
"The current antiretroviral therapy for HIV/AIDS is not a cure, and the side effects from lifelong use are significant. Also, the yearly average cost of treatment on anti-retroviral is $14,000 to $20,000 per year, and the average lifetime cost is calculated as $379,000. The cost of an anti-HIV therapy we propose would be a fraction of these costs as the treatment would be for a limited time and not require life-long use.
What has ENZC accomplished since the merger process began (September 15, 2020-December 30, 2020)?
1. Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis
2. Enzolytics, Inc. Engages BTS Research to Conduct Toxicity Study
3. Opened Laboratory on the campus of Texas A&M University in the University's Institute for Preclinical Studies.
4. Successfully raised necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.
5. The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years.
6. We have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
7. Testing of the newly produced monoclonal antibodies is also being arranged. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France.
8. Since the signing of the original non-binding letter of intent, the Company has filed two annual reports and eight quarterly reports, with the required OTC alternative reporting supplemental information, and will soon be filing the last quarterly filing and opinion letter with OTC Markets needed to bring the Company to a current status.
9. By combining our expertise with outside professionals and trusted consultants, we have succeeded in less than three months in accomplishing each of these items - as well as others.
Sometimes things aren't clear right away. That's where you need to be patient and persevere and see where things lead.
Mary Pierce
What has ENZC accomplished since January 1, 2021 to present day)?
1. 02/07/2021 Annual Report - Corrected Annual Report 12-31-2020
2. 01/11/2021 Attorney Letter with Respect to Current Information - Attorney Letter for 12-31-2019, 2018 and related Qtrs 3-31-2020, 6-30-2020 and 9-30-2020
3. 01/11/2021 Quarterly Report - For the period ended September 30, 2020 Disclosure Information
4. 01/11/2021 Quarterly Report - For the period ended June 30, 2020 Disclosure Information
5. 01/11/2021 Quarterly Report - For the period ended March 31, 2020 Disclosure Information
6. 01/11/2021 Annual Report - Annual Report Disclosure information December 31, 2019
7. 01/11/2021 Annual Report - Annual Report for the Year Ended December 31, 2019
8. 01/11/2021 Annual Report - Annual Report Disclosure Information Corrected 12-31-2018
9. 01/07/2021 Quarterly Report - For the period ended June 30, 2020 06/30/2020
10. 01/06/2021 Quarterly Report - For the period ending 9-30-2020
11. Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit.
12. Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application.
13. Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus.
14. Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases. COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu®.
15. Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments.
16. Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus).
17. Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus.
18. COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen.
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA.
Joyce Meyer
What do we know as shareholders?
We know what the company has told us and information we find through research and COMMON SENSE.
Some FACTS we KNOW:
1. AI has been a factor
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gilead?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
So what does all of this mean?
ENZC is not a scam as some people all over the internet would have you to believe. It needs money as any company would to run its operations. It has been successful thus far keeping the lights on. They will continue to need funding moving forward so that is something to watch for.
Why is so special about ENZC?
TWO things NO VIRUS ESCAPE and LOW TOXICITY.
The problem with many viruses is that they mutate. Many treatments for virus allows for mutations and may be toxic to other body functions.
Here is why ENZC are confident in their technology:
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
Thus, for the patient, immunotherapy will be remarkably different — it will be safer, provide a much-needed immunotherapeutic cure rather than requiring lifelong treatment and costs substantially less than current antiretroviral therapy.
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of its mission, the Company is testing these antibodies to prepare them for use as therapies against these diseases.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
ENZC is by no means a slam dunk however their technology is certainly different from other company’s technology that is on the market. There is still much work to be done as evident with the last press release. It is a LONG ROAD in the field of Biotechnology as nothing happens overnight however as companies make progress in their endeavors, the results sometimes can be earth-shattering.
The QUESTION is will ENZC have some EARTH-SHATTERING moments?
I BELIEVE SO
EZNZC checks many of the boxes of a good biotechnology to invest in. Good management, hot sector, collaborative support, product pipeline with potential are some of the boxes checked off. Another BIG plus for ENZC technology is that it will be at a reasonable price unlike many other drugs that come to the market that are cost prohibitive.
INSURANCE COMPANIES are going to LOVE ENZC while the COMPETITION are going to HATE us.
Paul Gleason
ENZC Website:
https://enzolytics.com/
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
ENZC or any Biotechnology stock does not need any PROMO.
The FACT of the matter is simple RESULTS drive BIOTECHNOLOGY stocks up down and all around.
11 Things to Know About Investing in Biotech Stocks
The biotech industry is super hot right now. Many of the companies out there have the potential to bring in huge returns, but the accompanying risks can be pretty steep. Besides that, not every biotech company and security are created equally. Before you start investing in the biotech industry, you should know a few characteristics of the sector and how to go about trading these tricky securities.
Takeaways:
Biotech stocks are high risk and high reward.
Researching the company is vital.
Active trading on biotech stocks is a must.
What Are Biotech Stocks?
The biotechnology industry uses living organisms to make commercial products, like pharmaceuticals and superior crops. In the stock world, biotech is often used as an umbrella term for any company that develops new drugs, whether the components are biological or not. This sector is constantly changing, growing, and developing as scientists discover new ways to treat illnesses and diseases, making biotechnology stocks a favorite investing choice for many traders.
Why Invest in Biotech Stocks?
People invest in biotech stocks for many reasons. First, many investors feel good about investing in a company that’s trying to help people live longer, healthier lives. Second, if the potential drug is successful, investors stand to make an extraordinary return on their investment. Third, the potential for strategic trades is high with biotech stock since any piece of news, positive or negative, from the company can send the price skyrocketing or falling only to change course the next day with the introduction of new information.
How to Invest in Biotech
Biotech stocks are historically volatile. Often, the value of the stock is all speculative and based on the promise of a new drug or treatment. Until the drug proves viable, receives FDA approval, and hits the market, investing is a big gamble. However, stock prices for these companies are often very low right up until news breaks. If you do your research and get in early, you can make a tremendous amount of money in this sector. Follow these steps to vet any biotech investment you’re considering.
1. Determine the sector
As mentioned, ‘biotech’ can be used as an umbrella term for any pharmaceutical. If you want to invest in a true biotech company, one that works exclusively with biological material, you need to learn about what the company does rather than just looking at its designation.
2. Establish an acceptable risk
Know how much money you’re willing to risk if the stock goes south. Establishing this before you find a company you’re excited about will hopefully help you act judiciously when it’s time to actually pay out for shares rather than acting on impulse and emotion.
3. Know the downsides
Biotech is risky. Even the ‘safe’ bets carry risk. Keep these common disadvantages of biotech investments in mind:
Clinical trial failure: If the drug fails in clinical trials, the company has to essentially start the scientific process over, which can take an enormous amount of time and send its share price spiraling.
Approval delays: Regulatory approval can take a long time. Even if a drug does well in trial, until it comes to market, the stock value might plateau or drop.
Commercialization setbacks: With all approval in place, the company still has to get the drug to market and hope it sells.
Competition or patent problems: Sometimes, while waiting on steps like trials and approval, competitors will beat the company to market or the patent on the drug might run out. Either of these scenarios can damage the share value.
4. Assess the company’s history
Learn about the company. See how quickly they’ve gotten other drugs to market and whether or not those drugs have good commercial sales. Biotech companies pop up all the time with no history to review. These investments are particularly risky, but also offer some of the highest potential payouts if they’re successful.
5. Keep your portfolio diversified
Avoid putting too much of your money into the biotech sector. Keep your portfolio diversified in case your investment doesn’t pan out. Greed can lead to devastation.
6. Check-in regularly
Biotech stocks are not investments you can purchase and sit on for years. Keep track of price, volume, and news from the company to see if you should invest in more stock, part with the shares you have before losing money, or sell at a profit.
Tips for Investing in Bio Stocks
Use these 11 tips to help you find great potential investments in the biotech industry and make data-driven, research-based trading decisions.
Know Where the Company is in the Process
It might cost slightly more to get in when a company is out of the clinical trial stage of product development, but it could potentially save you from losing a lot of money if they don’t even make it that far in the process. It’s important to know where the company is in development before buying in.
Consider Risk
Know the risk the company presents. You’ll want to assess history, stage of development, pipeline, partners, cash-on-hand to debt and ‘potential’ cash, and the company’s leadership and reputation. If you feel uneasy about more than two or three of these factors, it might not be the best risk level for you.
Look for Companies With Multiple Plans
It’s tempting to put all your money into a company that’s focused on a single product and putting all its money and resources into it. However, it’s often a safer investing move to find a company that has several ongoing projects in case its front runner fails.
See Who Is Investing
Look and see who’s investing in the company. Often, big-name companies, either in the industry or even some from outside, will put money into the biotech firm’s research and development. You want a solid amount of funding from reputable sources.
Find Companies With Partners
Support, support, support. Any company at risk of going under should their one drug lose viability is not a great investment. Look for companies with partners who can continue project funding should the front-running drug fail at some stage in the development process.
Know the Cash to Biobucks Ratio
The biotech industry uses the term ‘biobucks’ as a synonym for potential payouts should their drug make it to market. Many biotech firms calculate their support using upfront cash and biobucks. If you see an announcement that a biotech firm just got a huge deal, look at the fine print to see how much of that is cash now and how much is conditional.
Look Past the Press Releases
Reading the news about the company and its development progress isn’t enough. You need to dig into its research and see how frequently researchers are performing clinical trials compared to how often you see ‘news’ about the company. You want actual progress, not just the illusion of progress.
Read the Reports
Take the time to review the actual reports on clinical trials. It’s easy enough to spin findings positively for a layman’s press release. It’s harder to disguise facts in a scientific study. You could get ahead of a bad move by checking the real numbers.
Look at the Competition
Multiple companies competing over the same treatment can help boost stock prices, but if you side with the losing company, you could be out a lot of money. Consider investing in companies that don’t have any immediate competition.
Consider the Leadership
Look at the leaders of the company. Learn about their history, management style, risk tolerance, and other characteristics. You want to invest in a company with trustworthy and capable leaders.
Avoid Emotional Investing
If you find yourself getting super excited about a potential investment and itching to hit that buy button without any research, take a minute to calm down. Emotional investing without the facts can lead to disaster in the biotech industry.
https://ragingbull.com/biotech-stocks/11-things-to-know-about-investing-in-biotech-stocks/
Does a Drug Approval Mean Higher Stock Price?
Answering the question, "Does a Drug Approval Mean a Higher Stock Price?" is fairly straight forward, but there are some caveats that investors need to be aware of. The simple answer is yes, in most cases a new drug approval can lead to a higher share price for the company on the receiving end of that approval. However, each company and approval need to be considered individually so investors can avoid drug approval disappointment.
What Is The Approved Drug?
The word "blockbuster" is often used in association with new drug approvals and history has shown that is exactly what a company needs to have approved to ensure its shares skyrocket post-approval. Examples of potential blockbuster drugs would include, but are not limited to, treatments for cancer, diabetes and sexually transmitted diseases. Another way of looking at this situation is this. A pharmaceutical company has just received approval to sell a new treatment for common allergy symptoms. While that drug may eventually prove to be an important part of the company's revenue stream, it is used to treat a mundane condition and unlikely to really jolt the company's shares.
What Company Is Getting The Approval?
In some cases, the company on the receiving end of a new drug approval is almost as important as what drug is being approved. In this case, before approval, investors should evaluate the potential impact of the new drug on the company's top and bottom lines. For example, there have been examples of small biotechnology companies that, because of funding constraints, only work on one or two major treatments at a given time. Financial markets are aware of this and when those companies land drug approvals, the shares usually surge. On the other hand, an established, large-cap pharmaceuticals company can land a new drug approval, but if that drug is only expected to account for a small percentage of profit and revenue, the approval is unlikely to do much for the share price.
Who Is Doing The Approving?
When it comes to regulatory bodies that affect a drug company's share price, none exceed the importance of the U.S. Food and Drug Administration. Arguably, the only entity that comes remotely close is the European Union's equivalent of the FDA. That is to say a company may get its new blockbuster drug approved in Brazil, but that alone is unlikely to have a significant impact on the shares. The company's investors will want to see the drug approved in the U.S. or Europe, preferably both, for maximum reward on their investment.
Consider Costs
Many new blockbuster drugs, particularly those that treat cancer or genetic diseases, are expensive. Related to the issue of pure cost is whether or not health insurance providers will help their patients make up the difference in purchasing expensive new drugs. Bottom line: If a new drug is ultra-expensive to the point that it cannot be accessed by patients and insurance providers are reluctant to absorb the cost, the manufacturer is not going to sell much of that drug and that is not good for the share price.
https://finance.zacks.com/drug-approval-mean-higher-stock-price-8390.html
Choosing Biotech Stocks
Investing in biotechnology can be a risky business. The following list outlines some suggested criteria to consider when choosing which biotech stocks to buy.
HOT Areas of Research
Watch for companies researching areas such as cancer, AIDS, diabetes, heart disease, neurological diseases, immunological diseases, viral infections and tissue regeneration, where there is a high degree of incidence in the population. Success in these areas will ensure the company a ?faster return on their investment in R&D and licensing efforts. An alternative is to invest in a niche company with an orphan drug that, if successful, is protected from competition for several years.
Collaborative Support
A strong network of collaborative support is an indication that a company is financially and logistically stable. A small company, despite having good ideas, might find it difficult to go it alone, but can benefit immensely from the backing of one or more larger corporations. Several sponsors provide added security since the withdrawal of support from one collaborator might result from missed milestones, strategic differences or a general loss of interest in a project.
Ample Long-Term Funds
Some financial advisors say to select companies with at least 2 years of cash reserve. It takes many years to license a product, however, and even longer to recoup the costs of developing it. There are many different options for financing a startup, so investigate new companies carefully. It's also important to consider where more established companies get their funding, and whether there is potential for more if needed. For publicly owned companies, you must judge whether they have excessively diluted their shares. Companies with private financing, milestone payments and sale of debt securities (secured and/or convertible) have more potential for stability than those without any of these sources.
Low Debt
In addition to looking for companies with sufficient funding to support their future research efforts and necessary R&D to get a product to market, it is important to watch for those that won't be spending all of that funding paying off debts. Look for a company that hasn't already taken out excessive loans, from banks or private investors, to get started.
Pipelines With Potential
Look for ?companies with pipelines consisting of more than one product. Those with at least 2 products in clinical trials are safer than those with only one good idea. If one product fails, there's always the second to fall back on. A company with several products in various stages of development might be spread too thin, although it also might have multiple routes to success.
Market-Ready Products
Look for companies with products that are nearing the end of the R&D/ FDA approval process and can be realistically expected to hit the market sooner than later. Of course, by this stage, success is still not guaranteed but if the bulk of stringent testing is completed there is a higher likelihood that you will soon see some return on your investment. It's a good idea to watch for new drugs that have reached the stage of clinical testing on human test subjects since animal models are not always a reliable indicator of efficacy and safety. Tests on cell lines may reveal even less about a candidate drug.
Rebound Potential
Previously highly valued stock might be found at a lower price if the company has recently gone through a rough patch and experienced some difficulties. The stock market is often hard on companies that hit a temporary glitch, overreacting to any news, whether it is good or bad. This is particularly true for the biotech industry. Prices might drop dramatically as a result of slightly bad news causing public perception to suffer and investors to panic. But, although the company once had promise, a low share price isn't the only criteria you should be looking for. Before buying up these cheap stocks, be certain that the glitch is something that can be fixed.
Good Management
It's important that a biotech company is being managed by knowledgeable, business-savvy entrepreneurs, but companies whose managers also have a scientific background or research experience (a Ph.D. or MD) are also recommended by seasoned investors. One of the benefits of obtaining a doctorate, that these individuals have, is the technical knowledge to understand the business they are in and fully grasp the ramifications of research data as it becomes available. Using that understanding, they are more likely to make sensible decisions about how company resources are allocated, choosing the best candidate drugs and research strategies.
https://www.thebalance.com/choosing-biotech-stocks-375644
The Ups And Downs Of Biotechnology
Many traders dream of the day they can close out their positions and realize that one big gain. You've probably heard stories of novice traders who built up their trading accounts from mere thousands into millions.
Biotechnology is a sector where traders seek out these huge profits. For smart traders, this sector can present an incredible area of opportunity, but for those who are not willing to do their homework, it can be a train wreck waiting to happen. We'll use real-life examples to illustrate why this sector can be so appealing and what issues you should consider before putting your capital at risk.
KEY TAKEAWAYS
Investors are often tempted to look at the biotech sector for high return investments.
Investing in biotech, however, comes with risks, in part due to the fact that many of the products being researched or developed will never make it to market.
Biotech firms face many regulations as well, including from the FDA, which adds risk to the already volatile nature of developing new drugs.
The products produced in this sector are complex, where it would take the average investor significant time to understand the factors that affect the product’s chances of success.
Even large financial institutions tend to have a poor track record when it comes to predicting the performance of these companies.
The Big Win
Few sectors in the market see small single-product companies go from having tiny market capitalizations to having a worth over hundreds of millions practically overnight. The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough.
As an example, as you can see in Figure 1, Novavax Inc. (NVAX) rose from a low of $0.74 in August 2005 to a high of $8.31 in March 2006. This is equal to an amazing 1,023% in seven short months. With gains like this, it is easy to see why so many are anxious to put money into this sector.
It's Not All Roses
You can't always put down $10,000 and come back in seven months to collect $102,300. Along with the opportunity to make huge gains comes the potential for some very devastating losses. Because most of the companies in this sector are relatively small, with no more than two or three products, news releases concerning their clinical trials and/or approval from the Food and Drug Administration (FDA) is one of the main factors deciding the direction of the company's stock. Companies in this sector can live and die by these announcements.
For example, investors of Threshold Pharmaceuticals (THLD) saw the price of their shares travel to a high of $16.98 in mid-April 2006 only to fall to a low of $3 in mid-May 2006. The major fall was attributed to the termination of the company's clinical trials upon the FDA's request. The 82% drop in roughly one month is a good example of what can happen when a company releases this type of bad news.
Even worse, notice in Figure 2 how the stock gaps down. This means that you have no chance of cutting losses once you've entered the trade. As an example, let's say that you bought the stock at around $15 and had a stop-loss order in for $13. In theory, the stop-loss should limit your loss to around $2 ($15 - $13). In volatile markets like this, however, you can't limit your loss. Your order will get filled at the open price of $3, not the $13 you wanted.
The Illusion of the Story
Many investors get wrapped up in the story of a small biotech firm and convince themselves that the company's product(s) will revolutionize its industry. Some investors even place money into these types of companies simply because they believe that complex products seem so impressive that they must work. It's not that impressive-sounding products can't be successful, but rather that it is extremely difficult for the average investor to get a handle on the probabilities of success for a drug.
For example, an investor researching Micromet Inc. (MITI) would have read on its Yahoo! Finance page that "its drug development platform is based on its BiTE technology, an antibody-based format that uses the cytotoxic potential of T-cells. The company's principal product candidates include Adecatumumab (MT201), a recombinant human monoclonal antibody.”
This might sound impressive, but do you have any idea what the company does? Perhaps those of you with doctorates in biology understand, but for the average person (or the average analyst), even understanding the product can be difficult. What this means is that you, the investor, are going to have to do a lot of homework to figure out exactly what the product is, what the company's strategic advances are and what risks are involved in the event that the product does not work.
Nobody Really Knows, Not Even the Big Guys
Since the companies in this sector can be very complicated, many traders will turn to large financial institutions for guidance. The buy and sell ratings made by these companies can be used as a tool to determine whether or not an investment decision should be made, but as you can see in Figure 3, they can be totally wrong.
In our first example, an investment bank issued a buy rating on Valentis Inc. (VLTS) on June 23, 2006. Eleven trading days later, the company released bad news about its drug and the stock fell a whopping 79% in one day. What did the firm that issued the buy rating do? They downgraded the stock to a hold rating. That makes you wonder how poorly a company has to perform to get a sell rating.
Another example of poor financial institution advice occurred on December 8, 2005, when a large investment bank issued a buy rating on DOV Pharmaceuticals Inc. (DOVP). At this point in time, the price was approximately $15, but as you can see in Figure 4, this changed within the next few months as the stock dropped off and hit a low of $2.71. On May 17, 2006, the investment bank came out and (again) issued a hold rating, but this rating was not much help to investors as the stock dropped again, to a new low of $1.85 a month later.
Conclusion
The biotechnology sector is very exciting and can be very rewarding for those who remain cautious and do their homework. However, it is easy to get caught up in the dream of 1,000% gains, or the intriguing stories of how certain companies' products will change the world.
It is important to realize that if you are aiming for huge gains in the biotech sector, you likely will encounter some bad trades that will leave you reeling at the reduction of the value of your account. We all know that investors make mistakes and, as shown above, even the big players can see their picks lose most of their value. If the big players can be completely wrong, so can you, so trade with caution and restraint. When it comes to investing in this high-risk sector, it may be wise to use only as much money as you can afford to lose.
https://www.investopedia.com/articles/trading/06/biotechsector.asp
PCOAB Audit
We have engaged the Auditor to issue an audited statement in order to achieve our goal of fully reporting by April, if not sooner. One of our top priorities is finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria. We have received proposals from FDA approved manufacturers to produce the quantities necessary for such certification and those are under review. Our lab at Texas A & M University meets our exact needs for completing development of additional monoclonal antibodies for treatment of the HIV and SARS-CoV-2 viruses," stated Charles Cotropia, CEO.
https://marketwirenews.com/news-releases/enzolytics-inc-engages-pcaob-auditor-for-december-31-7746818055730032.html
Barbara Johnson
So it can RISE 10X-15X in the next 45 DAYS!!!
There is no LIMIT for ENZC stock price appreciation!!!
— Paul Ehrlich
Too much going on with ENZC.
The company could drop press release any time that WILL send the stock past all previous HIGHS!
FACTS we KNOW:
1. AI
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month (April 2021)
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gileads?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
Enzolytics takes rapid strides in achieving one of the many milestones.
$ENZC #HIV #ENZC #OTCQB #COVID19 #EMA #FDA #patents ITV-1
The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:
HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.
Very very HUGE OTC LESSON HERE:
Elizabeth Taylor
Multiple Millionaires have been made and more WILL BE MADE as ENZC's stock price APPRECIATES!!!
Why?
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
SPRING is in the Air
BOOM Time COMING
Here is why we are confident in our technology.
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
Mary Pierce
Now IM really CONFUSED!!!
There is IMMB
There is IMMB BG
There is Immunotech Laboratories BG
There is Immunome
Will the real IM PLEASE stand UP
Immunome
We like a very liquid stock.
Shares changing hands, volume going up.
ENZC is percolating for the next leg UP
Many Many things are going on with ENZC.
Many predictions have made and haven't yet come to fruition.
A prediction deferred is not a prediction denied.
Some may expect certain things this week however they may not happen to next week or the week after.
ALL is GOOD!!!!
What we expect that is imminent in the next 15-45 days:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. 2020 Annual Report/PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
BOOM time COMING!!!
Eli Lily wasn't playing nice last October however me thinks they are playing nice now:
The critical nature of targeting immutable sites on the Coronavirus will be the same. I note the recent news that Eli Lilly has paused its anti-Coronavirus monoclonal antibody trials. We are not privy to the underlying reasons for such pause, but this could be due to failure to target immutable sites on the virus or on the methodology for producing the monoclonal antibodies. When we recently asked Eli Lilly for the identity of the binding sites for its anti-Coronavirus monoclonal antibodies, they were unable to share that information with us. The fact is that multiple neutralizing antibodies will be necessary to control the Coronavirus, just as is the case with HIV. Our program is to produce multiple antibodies each targeting conserved, immutable sites on the virus.
https://www.biospace.com/article/releases/enzolytics-inc-shares-bioclonetics-immunotherapeutics-inc-company-update/
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
Very very HUGE OTC LESSON HERE:
Multiple Millionaires have been made and more WILL BE MADE as ENZC's stock price APPRECIATES!!!
Why?
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
SPRING is in the Air
BOOM Time COMING
ENZC is not a pump and dump stock.
What is a pump and dump stock?
Typically a pump and dump scam occurs when fraudsters boost the company's stock price by sharing positive, but fake, information. Scammers buy up the shares cheap before spreading the rumors that drive the stock price higher and higher and encourage other investors to get in on the supposed windfall.
There is NOTHING FAKE about ENZC!!!
Why ENZC is not a pump and dump stock?
1. They are PINK current on the OTC, filed financial reports and paid money
to do so.
2. They spent money to file patents.
3. The spent money to hire a PCOAB auditor to audit financials from 2019 and 2020.
4. ENZC spent money to have toxicity tests done.
5. ENZC spent money to have AI analysis to to identify conserved epitopes.
6. ENZC spent money to conduct an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity.
7. ENZC spent money to produce monoclonal antibodies.
8. ENZC spent money to lease laboratory space at Texas A&M.
pump and dump stocks SURELY don't spent money on ACTVITIES that ENZC has.
As a a RESULT of these ACITVUTIES by ENZC we are waiting for the following INFORMATION:
FACTS we KNOW:
1. AI
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gileads?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:
HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.
FACTS not fiction
1. A PR CAN'T EVEN GET THE PRICE UP. WRONG
Press Releases do not drive up stock prices, RESULTS from the company does.
2. IT'S NOW A SELL THE NEWS DEAL AFTER THAT PR. WRONG
For TRADERS/FLIPPERS only!!! Long term holders will hold their shares for better returns.
3. NO OTHER GREAT NEWS IS COMING ANY TIME SOON. WRONG
Yea right that is a figment of your imagination.
There is no LIMIT for ENZC stock price appreciation!!!
Too much going on with ENZC.
The company could drop press release any time that WILL send the stock past all previous HIGHS!
4. WITH NO GREAT NEWS COMING, PEOPLE WILL LOSE INTEREST AND MOVE TO THE NEXT PLAY. WRONG
LONG TERM HOLDERS are here to stay waiting for and will get their DOLLAR price ranges.
5. TOO MANY UNSECURED NOTES. WRONG
Those too many UNSECURED NOTES was here when ENZC ran to over 90 CENTS and will be here when ENZC runs to DOLLARS!!!
6. NO PROOF OF ANY SHARES BEING LOCKED UP. WRONG
The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years. We believe this step, along with the reorganization under Section 251 G that was initiated prior to the closing of the combination agreement, will significantly enhance the equity position of the Company.
https://marketwirenews.com/news-releases/enzolytics-inc-2020-year-end-update-6713954951124293.html
7. THE DAILY CHART SHOWS A DOWN TREND WITH LOWER LOWS. WRONG
Charts are not DRIVING ENZC CHARLES is!!!
8. 1,584,725,795 – 1.584 BILLION UNRESTRICTED SHARES WRONG
ENZC SECURITY DETAILS
Share Structure
Market Cap Market Cap
1,076,925,548
03/09/2021
Authorized Shares
3,000,000,000
02/28/2021
Outstanding Shares
2,797,935,953
02/28/2021
Restricted
735,839,585
02/28/2021
Unrestricted
2,062,096,368
02/28/2021
Held at DTC
1,770,323,548
02/28/2021
Float
1,670,830,512
09/30/2020
9. THEY WON'T UPDATE THE FLOAT! WRONG
The FLOAT will be updated in near future when the 2020 annual is released.
FACTS not fiction
1. A PR CAN'T EVEN GET THE PRICE UP. WRONG
Press Releases do not drive up stock prices, RESULTS from the company does.
2. IT'S NOW A SELL THE NEWS DEAL AFTER THAT PR. WRONG
For TRADERS/FLIPPERS only!!! Long term holders will hold their shares for better returns.
3. NO OTHER GREAT NEWS IS COMING ANY TIME SOON. WRONG
Yea right that is a figment of your imagination.
There is no LIMIT for ENZC stock price appreciation!!!
Too much going on with ENZC.
The company could drop press release any time that WILL send the stock past all previous HIGHS!
darron427 you are 100 PERCENT CORRECT!!!
You said:
Anyone who thinks ENZC is a scam, pipe dream, unrealistic play, improbable, impossible, fake, not feasible or whatever adjective you chooses to use, I have nothing to say however I let Jack say it to you:
darron427,
You said:
We at ENZC follow the SCIENCE and SCIENCE leads to results
Very very HUGE OTC LESSON HERE:
Multiple Millionaires have been made and more WILL BE MADE as ENZC's stock price APPRECIATES!!!
Why?
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
SPRING is in the Air
BOOM Time COMING
I found this:
Valued at $23million 4 months ago, now pushing $1billion
Who That?
ENZC
Here is why we are confident in our technology.
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
Never Mind I found it!!! Texas A&M University
BIOSCIENCE BUSINESS ACCELERATOR
If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.
Speed Up the Commercialization Process
By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.
Standard Lease Terms
Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.
Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.
Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.
Included with Lease
• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address
Evaluation Criteria
Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.
Applications are evaluated on the following criteria:
• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity
https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator
Where is ENZC working currently?
The information darron427 provides is old and part of the old business dealings of ENZC and not part of the NEW and BOLD ENZC that will revolutionize medical therapeutic treatments.
Does ENZC have any PATENTS approved by a GOVERNMENT AGENCY?
Yes
NO
MAYBE 19!!!